Profil de l'entreprise

Vous venez de lire:

Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone

Nouvelles fournies par

Resverlogix Corp.

May 30, 2017, 07:00 ET